MVM Partners

MVM Partners

Founded in 1997 by a team of healthcare investment specialists, MVM Partners operates from London, Boston, and the San Francisco Bay Area. The firm was purpose-built for healthcare, not as a generalist fund that drifted into the sector, and its longevity—over two decades—has outlasted most specialist peers. MVM does not trace its capital to a single wealthy family or a large institutional anchor seeded for diversification purposes. MVM pursues growth-stage and expansion-stage investments across the healthcare and life-sciences spectrum, from medical devices and pharmaceuticals to diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing. The firm typically commits $20 million to $100 million in equity per company and has a track record that includes both acquisitions and initial public offerings. Confirmed active portfolio companies include Axonics, a medical device developer, and Paragon 28, a foot-and-ankle orthopedic company. MVM invests primarily in North America and Europe, with a focus on products that demonstrate a durable competitive moat through intellectual property, regulatory exclusivity, or unique branding. MVM manages over $1 billion in assets (Altss estimate) and invests from a concentrated portfolio, which suggests a strategy built on high-conviction bets with close management-team engagement rather than broad index-style exposure. The firm maintains offices in London, Boston, and the San Francisco Bay Area. MVM does not publicly disclose its current fund vehicles, nor does it list a specific roster of investment professionals by name. The firm does not operate a public-facing philanthropic foundation and has not characterized itself as a multi-family office or co-investment club. MVM is structured as a pure-play healthcare private equity firm that spans both venture and later-stage financing, a dual posture that distinguishes it from early-stage-only venture firms or large-cap generalist buyout shops. A management team may tap MVM for minority growth capital with the same platform that can later lead a take-private or a buyout, creating a single-relationship capital stack that can follow a company from commercial validation through exit. This hybrid structure is less common in life sciences, where funding pathways typically require a handoff from venture investors to crossover funds or large strategics.